| Dr Bobby Leonard Shelton Ii, MD | |
|
1500 Commonwealth Ave, Williamsburg, VA 23185-5229 | |
| (757) 585-2200 | |
| Not Available |
| Full Name | Dr Bobby Leonard Shelton Ii |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 28 Years |
| Location | 1500 Commonwealth Ave, Williamsburg, Virginia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1386672509 | NPI | - | NPPES |
| 010386934 | Medicaid | VA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | 046246 (Georgia) | Secondary |
| 207L00000X | Anesthesiology | 0101240641 (Virginia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Riverside Doctors' Hospital Of Williamsburg | Williamsburg, VA | Hospital |
| Riverside Walter Reed Hospital | Gloucester, VA | Hospital |
| Riverside Regional Medical Center | Newport news, VA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| American Anesthesiology Of Virginia Pc | 6800790023 | 524 |
News Archive
Apricus Biosciences, Inc. and Elis Pharmaceuticals, announced today that the two companies have entered into a licensing agreement granting Elis the exclusive rights to market Apricus Bio's new drug for erectile dysfunction, Vitaros®, in the Gulf and part of the Middle East. "This new agreement is the next step in our strategy of seeking to partner Vitaros in more than 100 countries around the world," said Dr. Bassam Damaj, President and Chief Executive Officer of Apricus Bio.
Arrowhead Research Corporation, a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it recently filed an application for approval to begin a phase 2a clinical trial of its RNAi-based therapeutic candidate, ARC-520, for the potential treatment of chronic hepatitis B virus infection.
"The rest of the world has embraced e-mail, online forms and iPhone apps, but health care still communicates in the centuries-old technology of paper," McClatchy/Tribune News reports. Now, technology companies are recognizing a business opportunity in that shortcoming. Moving to electronic medical records can be expensive - Kaiser Permanente spent $4 billion switching from paper to digital - meaning money in the bank for well-poised vendors.
Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced results from a 12-week, placebo-controlled Phase IIb study involving 79 patients with active rheumatoid arthritis ("RA") for its proprietary drug CF101, an A3 adenosine receptor ("A3AR") agonist.
› Verified 4 days ago
| Entity Name | North American Partners In Anesthesia (virginia), Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922031442 PECOS PAC ID: 9931192739 Enrollment ID: O20041217000009 |
News Archive
Apricus Biosciences, Inc. and Elis Pharmaceuticals, announced today that the two companies have entered into a licensing agreement granting Elis the exclusive rights to market Apricus Bio's new drug for erectile dysfunction, Vitaros®, in the Gulf and part of the Middle East. "This new agreement is the next step in our strategy of seeking to partner Vitaros in more than 100 countries around the world," said Dr. Bassam Damaj, President and Chief Executive Officer of Apricus Bio.
Arrowhead Research Corporation, a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it recently filed an application for approval to begin a phase 2a clinical trial of its RNAi-based therapeutic candidate, ARC-520, for the potential treatment of chronic hepatitis B virus infection.
"The rest of the world has embraced e-mail, online forms and iPhone apps, but health care still communicates in the centuries-old technology of paper," McClatchy/Tribune News reports. Now, technology companies are recognizing a business opportunity in that shortcoming. Moving to electronic medical records can be expensive - Kaiser Permanente spent $4 billion switching from paper to digital - meaning money in the bank for well-poised vendors.
Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced results from a 12-week, placebo-controlled Phase IIb study involving 79 patients with active rheumatoid arthritis ("RA") for its proprietary drug CF101, an A3 adenosine receptor ("A3AR") agonist.
› Verified 4 days ago
| Entity Name | American Anesthesiology Of Virginia Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417994872 PECOS PAC ID: 6800790023 Enrollment ID: O20080812000606 |
News Archive
Apricus Biosciences, Inc. and Elis Pharmaceuticals, announced today that the two companies have entered into a licensing agreement granting Elis the exclusive rights to market Apricus Bio's new drug for erectile dysfunction, Vitaros®, in the Gulf and part of the Middle East. "This new agreement is the next step in our strategy of seeking to partner Vitaros in more than 100 countries around the world," said Dr. Bassam Damaj, President and Chief Executive Officer of Apricus Bio.
Arrowhead Research Corporation, a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it recently filed an application for approval to begin a phase 2a clinical trial of its RNAi-based therapeutic candidate, ARC-520, for the potential treatment of chronic hepatitis B virus infection.
"The rest of the world has embraced e-mail, online forms and iPhone apps, but health care still communicates in the centuries-old technology of paper," McClatchy/Tribune News reports. Now, technology companies are recognizing a business opportunity in that shortcoming. Moving to electronic medical records can be expensive - Kaiser Permanente spent $4 billion switching from paper to digital - meaning money in the bank for well-poised vendors.
Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced results from a 12-week, placebo-controlled Phase IIb study involving 79 patients with active rheumatoid arthritis ("RA") for its proprietary drug CF101, an A3 adenosine receptor ("A3AR") agonist.
› Verified 4 days ago
| Entity Name | Professional Anesthesia Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1619149648 PECOS PAC ID: 8527133677 Enrollment ID: O20090122000416 |
News Archive
Apricus Biosciences, Inc. and Elis Pharmaceuticals, announced today that the two companies have entered into a licensing agreement granting Elis the exclusive rights to market Apricus Bio's new drug for erectile dysfunction, Vitaros®, in the Gulf and part of the Middle East. "This new agreement is the next step in our strategy of seeking to partner Vitaros in more than 100 countries around the world," said Dr. Bassam Damaj, President and Chief Executive Officer of Apricus Bio.
Arrowhead Research Corporation, a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it recently filed an application for approval to begin a phase 2a clinical trial of its RNAi-based therapeutic candidate, ARC-520, for the potential treatment of chronic hepatitis B virus infection.
"The rest of the world has embraced e-mail, online forms and iPhone apps, but health care still communicates in the centuries-old technology of paper," McClatchy/Tribune News reports. Now, technology companies are recognizing a business opportunity in that shortcoming. Moving to electronic medical records can be expensive - Kaiser Permanente spent $4 billion switching from paper to digital - meaning money in the bank for well-poised vendors.
Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced results from a 12-week, placebo-controlled Phase IIb study involving 79 patients with active rheumatoid arthritis ("RA") for its proprietary drug CF101, an A3 adenosine receptor ("A3AR") agonist.
› Verified 4 days ago
| Entity Name | Northstar Anesthesia Of Virginia, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194488791 PECOS PAC ID: 6608268826 Enrollment ID: O20221205003063 |
News Archive
Apricus Biosciences, Inc. and Elis Pharmaceuticals, announced today that the two companies have entered into a licensing agreement granting Elis the exclusive rights to market Apricus Bio's new drug for erectile dysfunction, Vitaros®, in the Gulf and part of the Middle East. "This new agreement is the next step in our strategy of seeking to partner Vitaros in more than 100 countries around the world," said Dr. Bassam Damaj, President and Chief Executive Officer of Apricus Bio.
Arrowhead Research Corporation, a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it recently filed an application for approval to begin a phase 2a clinical trial of its RNAi-based therapeutic candidate, ARC-520, for the potential treatment of chronic hepatitis B virus infection.
"The rest of the world has embraced e-mail, online forms and iPhone apps, but health care still communicates in the centuries-old technology of paper," McClatchy/Tribune News reports. Now, technology companies are recognizing a business opportunity in that shortcoming. Moving to electronic medical records can be expensive - Kaiser Permanente spent $4 billion switching from paper to digital - meaning money in the bank for well-poised vendors.
Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced results from a 12-week, placebo-controlled Phase IIb study involving 79 patients with active rheumatoid arthritis ("RA") for its proprietary drug CF101, an A3 adenosine receptor ("A3AR") agonist.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Bobby Leonard Shelton Ii, MD 8553 Terrior Lane, New Kent, VA 23124 Ph: (540) 538-4447 | Dr Bobby Leonard Shelton Ii, MD 1500 Commonwealth Ave, Williamsburg, VA 23185-5229 Ph: (757) 585-2200 |
News Archive
Apricus Biosciences, Inc. and Elis Pharmaceuticals, announced today that the two companies have entered into a licensing agreement granting Elis the exclusive rights to market Apricus Bio's new drug for erectile dysfunction, Vitaros®, in the Gulf and part of the Middle East. "This new agreement is the next step in our strategy of seeking to partner Vitaros in more than 100 countries around the world," said Dr. Bassam Damaj, President and Chief Executive Officer of Apricus Bio.
Arrowhead Research Corporation, a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it recently filed an application for approval to begin a phase 2a clinical trial of its RNAi-based therapeutic candidate, ARC-520, for the potential treatment of chronic hepatitis B virus infection.
"The rest of the world has embraced e-mail, online forms and iPhone apps, but health care still communicates in the centuries-old technology of paper," McClatchy/Tribune News reports. Now, technology companies are recognizing a business opportunity in that shortcoming. Moving to electronic medical records can be expensive - Kaiser Permanente spent $4 billion switching from paper to digital - meaning money in the bank for well-poised vendors.
Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced results from a 12-week, placebo-controlled Phase IIb study involving 79 patients with active rheumatoid arthritis ("RA") for its proprietary drug CF101, an A3 adenosine receptor ("A3AR") agonist.
› Verified 4 days ago
Tushar Umakant Gajjar, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 120 Kings Way, Suite 2700, Williamsburg, VA 23185 Phone: 757-221-0110 Fax: 757-221-0851 | |
Jill N Hester, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 301 Monticello Ave, Anesthesia Dept, Williamsburg, VA 23185 Phone: 757-354-4135 Fax: 757-259-6597 | |
Stephen P White, DO Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 301 Monticello Ave, Williamsburg, VA 23185 Phone: 757-259-6622 | |
Putul P Rogowski, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 301 Monticello Ave, Anesthesia Dept, Williamsburg, VA 23185 Phone: 757-345-4135 Fax: 757-259-6597 | |
Elizabeth R Foxx, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 301 Monticello Ave, Anesthesia Dept, Williamsburg, VA 23185 Phone: 757-259-6622 Fax: 757-259-6597 | |
Satish Adawadkar, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 100 Sentara Cir, Williamsburg, VA 23188 Phone: 757-984-6000 |